Table 1 Demographic and clinicopathological features of cases
| Â | Â | N | % |
|---|---|---|---|
ER Status | Negative | 102 | 41% |
| Â | Positive | 145 | 59% |
HER2 Status | Negative | 106 | 43% |
| Â | Weak | 48 | 19% |
| Â | Moderate | 51 | 21% |
| Â | High | 42 | 17% |
TNM Stage | < = II | 184 | 71% |
| Â | > = III | 44 | 29% |
Grade | 1 or 2 | 108 | 50% |
| Â | 3 | 107 | 50% |
COX-2 | Negative | 75 | 30% |
| Â | Weak | 83 | 34% |
| Â | Moderate | 65 | 26% |
| Â | High | 25 | 10% |
pAkt Ser473 | Negative | 17 | 7% |
| Â | Weak | 29 | 12% |
| Â | Moderate | 59 | 24% |
| Â | High | 142 | 57% |
pAkt Thr308 | Negative | 14 | 6% |
| Â | Weak | 24 | 10% |
| Â | Moderate | 71 | 29% |
| Â | High | 134 | 55% |
pCaspase9 Ser196 | Negative | 38 | 15% |
| Â | Weak | 30 | 12% |
| Â | Moderate | 73 | 30% |
| Â | High | 106 | 43% |
pBAD Ser136 | Negative | 43 | 18% |
| Â | Weak | 41 | 17% |
| Â | Moderate | 76 | 31% |
| Â | High | 85 | 34% |
Survival | Alive | 159 | 64% |
| Â | Death from breast cancer | 78 | 32% |
| Â | Death from other causes | 11 | 4% |
Race | AA | 143 | 58% |
| Â | EA | 105 | 42% |
p53 mutation | Negative | 200 | 81% |
| Â | Positive | 48 | 19% |
Chemotherapy | No | 99 | 43% |
| Â | Yes | 132 | 57% |
|  |  | mean ± SD | |
Age at Diagnosis | (n = 248) | 55.0 ± 13.9 | |
Body mass index1 | (n = 236) | 29.0 ± 8.1 | |
CD31 | (n = 208) | 49.1 ± 43.9 | |